![](/wp-content/uploads/2018/10/phEAsTU8R9yBQYRCp6V4.png)
$599
Thoughts on Lexicon Closing Its Sota CVOTs
Yesterday, Lexicon announced the early close out of its sotagliflozin CVOTs, SCORED and SOLOIST, mainly due to operational challenges with COVID-19 and the low likelihood of finding a commercialization partner (press release). Below, FENIX provides highlights and insights surrounding this update, including the potential generalization to BI/Lilly’s EMPEROR HF studies, and larger thoughts on Lexicon’s pivot away from sotagliflozin.